Efficacy and safety of canakinumab, a long acting fully human anti-Interleukin-1β antibody, in systemic juvenile idiopathic arthritis with active systemic features: results from a phase III study

Efficacy and safety of canakinumab, a long acting fully human anti-Interleukin-1β antibody, in systemic juvenile idiopathic arthritis with active systemic features: results from a phase III study

Bibliographic Details
Main Authors: Ruperto, N, Brunner, H, Horneff, G, Quartier, P, Constantin, T, Berkun, Y, Erguven, M, Kallinich, T, Brik, R, Wulffraat, NM, Ferrandiz, MA, Rutkowska-Sak, L, Ozdogan, H, McCann, L, Lheritier, K, Preiss, R, Tseng, L, Martini, A, Lovell, DJ
Format: Online
Language:English
Published: BioMed Central 2011
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3194416/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3194416/

Similar Items